Revive Therapeutics Sees FDA Recommend Phase 3 For COVID-19 Related Study Of Bucillamine

Revive Therapeutics (CSE: RVV) announced major news this morning related to its ongoing study of Bucillamine, with the US Food and Drug Administration recommending that the company proceed straight to a phase three confirmatory clinical trial to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection.

The news is significant as it means that Revive will be able to skip over the phase two clinical study portion of the FDA’s process, enabling the product to get to market sooner than expected if proven effective against the infectious disease. The push to phase three on the study of Bucillamine will enable the company to expeditiously evaluate the safety and efficacy of the drug.

In addition to the recommendation provided, the FDA also provided guidance on the study design and outcome measures for the phase 3 study. More importantly, the FDA identified that as a result of Revive’s previous work with the drug on the treatment of gout, the data provided from that study could be used to skip over phase 1 and 2 of the clinical study process. The firms contract research team, Pharm-Olam, is actively working towards assembling the final investigation new drug (IND) for submission to the FDA within the next 60 days, after which the firm will begin its phase 3 trials.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Revive Therapeutics last traded at $0.18 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

US Individual Wealth Expected To Drop By 5% In 2020 While Indian And Chinese Households Get Richer

Not only has the coronavirus pandemic significantly crippled many economies around the world, but impacts...

Sunday, October 25, 2020, 11:37:00 AM

Consumer Confidence Falls to Lowest Level since March 2017; Dropping 9.5%

This morning the The Conference Board announced the Consumer Confidence Index declined sharply dropping 9.5%...

Tuesday, March 31, 2020, 01:03:19 PM

America’s Second Largest Shale Producer Chesapeake Energy Files for Bankruptcy Amid Oil Market Slump

As the demand for crude oil continues to remain low and inventories pile up amid...

Tuesday, June 30, 2020, 01:34:00 PM

US New Coronavirus Cases Continue to Break Daily Records

Despite the eagerness amongst Americans to return to the bustling activity once seen before the...

Friday, July 10, 2020, 05:31:00 PM

Coronavirus is Becoming 30% More Infectious After Mutated Strain Confirmed in Hong Kong

A new strain of the deadly coronavirus has been discovered in Hong Kong, and according...

Tuesday, July 14, 2020, 08:22:00 PM